Back to search results

A Trial of E303 for Advanced Solid Tumors

This study is testing a drug called E303 in people with advanced solid tumors that have either come back, spread, or haven't responded to standard treatments. E303 is an antibody-drug conjugate, which means it's designed to deliver a drug directly to cancer cells. All participants will receive E303 through an IV (into a vein). Researchers want to see how safe E303 is, how well people tolerate it, and if it can shrink tumors. The study is looking for side effects, serious side effects, and how many people have their tumors shrink after 32 weeks. This trial is currently in an unclear status and plans to enroll up to 149 participants.

Study design
This is a Phase I interventional study, meaning it's an early-stage trial focused on safety. It plans to enroll up to 149 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track adverse events and serious adverse events until the trial is completed, which is estimated to be 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07524348

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Samsung Bioepis Co., Ltd.
~149 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:E303

At a glance

Recruiting sites
6 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events and serious adverse events
Measured over Until trial completion (estimated 3 years)
+2 more outcomes measured

Conditions

Advanced Solid Tumors

Explore related trials

Solid Neoplasm

NCT07524348

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Research Site

    Scottsdale, Arizonano site contact published

    Recruiting

  • Research Site

    Fairfax, Virginiano site contact published

    Recruiting

  • Research Site

    Adelaide, Australiano site contact published

    Recruiting

  • Research Site

    Melbourne, Australiano site contact published

    Recruiting

  • Research Site

    Seoul, South Koreano site contact published

    Not yet recruiting

  • Research Site

    Barcelona, Spainno site contact published

    Recruiting

  • Research Site

    Madrid, Spainno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Samsung Bioepis
[email protected]
+82-32-728-0114
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.

Exclusion

Have spinal cord compression or clinically active central nervous system metastases
Have leptomeningeal disease
Have thromboembolic or clinically significant bleeding events
Have significant cardiovascular disease
Have an active autoimmune disease

What this trial measures

  • Incidence of adverse events and serious adverse eventsUntil trial completion (estimated 3 years)
  • Incidence of dose limiting toxicityFor the first cycle of treatment, through pre-dose Cycle 2 Day 1
  • Confirmed objective response rate32 weeks

    Efficacy endpoint per Blinded Independent Central Review (BICR), according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1